You save $69.98
CRISC Premium Bundle
- Premium File 1105 Questions & Answers
- Last Update: Nov 10, 2026
- Training Course 64 Lectures
- Study Guide 498 Pages
You save $69.98
A risk committee is deciding whether an unresolved exposure can be tolerated: A global bank commits to deploy privileged access management across 200 servers without funding or staff allocation. What is the most relevant avoidable consequence if the weakness remains unresolved?
An unfunded commitment creates false assurance and prolonged exposure on critical assets. This consequence follows from the specific missing governance or technical safeguard. Treatment feasibility depends on resourced ownership, not merely a nominal deadline. The appropriate response is: Replan treatment with verified resources, phased scope and risk-based priorities approved by sponsors.
Untested exit procedures can cause transaction gaps and prolonged settlement interruption. That potential consequence concerns third-party exit risk, rather than the direct risk described by resourcing and treatment. Here the material exposure is: An unfunded commitment creates false assurance and prolonged exposure on critical assets.
Local approval beyond authority can create invalid acceptance and unmanaged corporate exposure. That potential consequence concerns approval authority limit, rather than the direct risk described by resourcing and treatment. Here the material exposure is: An unfunded commitment creates false assurance and prolonged exposure on critical assets.
Excluding failures can give false assurance that backup recovery consistently works. That potential consequence concerns sampling independence, rather than the direct risk described by resourcing and treatment. Here the material exposure is: An unfunded commitment creates false assurance and prolonged exposure on critical assets.
Before making a treatment decision, an analyst is investigating this situation: A global bank commits to deploy privileged access management across 200 servers without funding or staff allocation. Which targeted first investigation would best clarify the risk before action is approved?
Compare approved budgets and engineer capacity with the server inventory and rollout schedule. This isolates the relevant cause before changing unrelated controls. An appropriate follow-up is: Replan treatment with verified resources, phased scope and risk-based priorities approved by sponsors.
Analyze utilization trends, service capacity and time-to-exhaustion history. That investigation concerns early-warning risk indicator and would not isolate the first implicated dependency here. The targeted check is: Compare approved budgets and engineer capacity with the server inventory and rollout schedule.
Compare exception expiries to active privilege inventory and recent approvals. That investigation concerns audit exception expiration and would not isolate the first implicated dependency here. The targeted check is: Compare approved budgets and engineer capacity with the server inventory and rollout schedule.
Inventory algorithms, signing dependencies and the confidentiality lifetime of stored data. That investigation concerns post-quantum transition risk and would not isolate the first implicated dependency here. The targeted check is: Compare approved budgets and engineer capacity with the server inventory and rollout schedule.
An organization is preventing a recurrence of this risk pattern: A global bank commits to deploy privileged access management across 200 servers without funding or staff allocation. Which ongoing safeguard would best prevent recurrence of this specific failure mode?
Require resource confirmation before classifying a risk action as committed. This safeguard addresses the recurring failure rather than only the current event. The expected verification is: The plan contains funded phases and tests proving sensitive servers moved under PAM controls.
Separate issue registers from confirmed incident classification workflows. That safeguard prevents failures associated with finding versus event confusion and does not directly prevent this resourcing and treatment recurrence. The applicable continuing control is: Require resource confirmation before classifying a risk action as committed.
Require independent population reconciliation before testing key controls. That safeguard prevents failures associated with sampling independence and does not directly prevent this resourcing and treatment recurrence. The applicable continuing control is: Require resource confirmation before classifying a risk action as committed.
Require evidence completeness gates before dashboards update to green. That safeguard prevents failures associated with missing control evidence and does not directly prevent this resourcing and treatment recurrence. The applicable continuing control is: Require resource confirmation before classifying a risk action as committed.
A risk leader is reviewing this situation: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. Which next step would most directly treat or govern the risk in this situation?
Escalate overdue treatment with current exposure and revise actions under accountable risk-owner decision. Action plans require accurate status and exception treatment when deadlines slip. Evidence that the action has worked would be: Management reports show late milestones, interim protections and a new authorized completion plan.
Agree an accountable risk decision owner and named implementing control owner through a joint governance decision. That change is aimed at orphaned remediation task, whereas this decision must address risk action overdue. The relevant first comparison is: Compare actual patch deployment evidence against agreed milestones and business impact.
Require a time-bound supplier action plan with evidence of containment and risk-owner escalation. That change is aimed at vendor vulnerability remediation, whereas this decision must address risk action overdue. The relevant first comparison is: Compare actual patch deployment evidence against agreed milestones and business impact.
Present risk exposure, trend versus tolerance, treatment decisions and impacts at a board-appropriate level. That change is aimed at board reporting relevance, whereas this decision must address risk action overdue. The relevant first comparison is: Compare actual patch deployment evidence against agreed milestones and business impact.
A risk owner seeks evidence following review of this situation: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. Which evidence would best demonstrate that the intended risk response is functioning?
Management reports show late milestones, interim protections and a new authorized completion plan. This evidence addresses the stated risk rather than showing only that a control was configured. Action plans require accurate status and exception treatment when deadlines slip.
The roadmap identifies vulnerable crypto dependencies, retained-data horizons and funded review milestones. That observation may help validate post-quantum transition risk, but it does not establish the acceptance condition for risk action overdue. Here, the decisive evidence is: Management reports show late milestones, interim protections and a new authorized completion plan.
The remediation plan has one funding sponsor, one implementing lead, and verified delivery milestones. That observation may help validate orphaned remediation task, but it does not establish the acceptance condition for risk action overdue. Here, the decisive evidence is: Management reports show late milestones, interim protections and a new authorized completion plan.
Supplier evidence documents current exposure, temporary protections, remediation milestone and closure test. That observation may help validate vendor vulnerability remediation, but it does not establish the acceptance condition for risk action overdue. Here, the decisive evidence is: Management reports show late milestones, interim protections and a new authorized completion plan.
A governance team is discussing the underlying cause in this situation: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. Which risk-management principle most directly explains the correct approach?
Action plans require accurate status and exception treatment when deadlines slip. The immediate management action is: Escalate overdue treatment with current exposure and revise actions under accountable risk-owner decision.
Data transformation errors can change governance decisions even when the original system is accurate. That principle is relevant to unvalidated data transformations, not the mechanism implicated by the stated risk action overdue situation. In this case: Action plans require accurate status and exception treatment when deadlines slip.
Emerging risks require periodic reexamination when technology introduces new trust and decision paths. That principle is relevant to generative ai emerging risk, not the mechanism implicated by the stated risk action overdue situation. In this case: Action plans require accurate status and exception treatment when deadlines slip.
Security exceptions need risk-owner authority; technical implementation requests alone do not constitute acceptance. That principle is relevant to exception approval conflict, not the mechanism implicated by the stated risk action overdue situation. In this case: Action plans require accurate status and exception treatment when deadlines slip.
A risk committee is deciding whether an unresolved exposure can be tolerated: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. What is the most relevant avoidable consequence if the weakness remains unresolved?
Hiding delays misleads decision-makers about ongoing exploitability. This consequence follows from the specific missing governance or technical safeguard. Action plans require accurate status and exception treatment when deadlines slip. The appropriate response is: Escalate overdue treatment with current exposure and revise actions under accountable risk-owner decision.
Raw alert counts can distract decision-makers from material enterprise threats. That potential consequence concerns board reporting relevance, rather than the direct risk described by risk action overdue. Here the material exposure is: Hiding delays misleads decision-makers about ongoing exploitability.
Uncorrected duplicates can inflate apparent incident trends and distort funding decisions. That potential consequence concerns duplicate incident counts, rather than the direct risk described by risk action overdue. Here the material exposure is: Hiding delays misleads decision-makers about ongoing exploitability.
Accepting a supplier promise without evidence can leave exploitable customer systems exposed. That potential consequence concerns vendor vulnerability remediation, rather than the direct risk described by risk action overdue. Here the material exposure is: Hiding delays misleads decision-makers about ongoing exploitability.
Before making a treatment decision, an analyst is investigating this situation: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. Which targeted first investigation would best clarify the risk before action is approved?
Compare actual patch deployment evidence against agreed milestones and business impact. This isolates the relevant cause before changing unrelated controls. An appropriate follow-up is: Escalate overdue treatment with current exposure and revise actions under accountable risk-owner decision.
Compare deployed routing and firewall state against prior risk assessment assumptions. That investigation concerns dynamic residual risk review and would not isolate the first implicated dependency here. The targeted check is: Compare actual patch deployment evidence against agreed milestones and business impact.
Test recovery steps and their identity evidence against privileged-account threat scenarios. That investigation concerns strong mfa recovery and would not isolate the first implicated dependency here. The targeted check is: Compare actual patch deployment evidence against agreed milestones and business impact.
Compare policy exclusions with business interruption dependencies and recovery objectives. That investigation concerns risk transfer limitations and would not isolate the first implicated dependency here. The targeted check is: Compare actual patch deployment evidence against agreed milestones and business impact.
An organization is preventing a recurrence of this risk pattern: A vulnerability treatment deadline passed, but reporting still shows 'on track' because the patch project remains open. Which ongoing safeguard would best prevent recurrence of this specific failure mode?
Automate overdue-risk escalation with evidence-based closure criteria. This safeguard addresses the recurring failure rather than only the current event. The expected verification is: Management reports show late milestones, interim protections and a new authorized completion plan.
Test alert workflow routing and overdue escalation periodically. That safeguard prevents failures associated with monitoring response gaps and does not directly prevent this risk action overdue recurrence. The applicable continuing control is: Automate overdue-risk escalation with evidence-based closure criteria.
Use retest criteria and management escalation for repeat findings. That safeguard prevents failures associated with repeat finding escalation and does not directly prevent this risk action overdue recurrence. The applicable continuing control is: Automate overdue-risk escalation with evidence-based closure criteria.
Require evidence completeness gates before dashboards update to green. That safeguard prevents failures associated with missing control evidence and does not directly prevent this risk action overdue recurrence. The applicable continuing control is: Automate overdue-risk escalation with evidence-based closure criteria.
A risk leader is reviewing this situation: An authentication fix depends on directory, application and help-desk teams but the treatment plan names only the application developer. Which next step would most directly treat or govern the risk in this situation?
Break down cross-team dependencies with accountable sponsors, prerequisites and joint acceptance tests. Complex risk treatment often depends on coordinated controls across multiple owners. Evidence that the action has worked would be: Milestones demonstrate directory policy, app integration and recovery workflow all operate together.
Agree an accountable risk decision owner and named implementing control owner through a joint governance decision. That change is aimed at orphaned remediation task, whereas this decision must address cross-team milestone dependency. The relevant first comparison is: Map the identity end-to-end transaction and identify team-specific control dependencies.
Open a tracked exception finding and require renewed authorized acceptance or removal of the offending access. That change is aimed at audit exception expiration, whereas this decision must address cross-team milestone dependency. The relevant first comparison is: Map the identity end-to-end transaction and identify team-specific control dependencies.
Map fourth-party dependencies and set continuity/exit controls for the shared service exposure. That change is aimed at fourth-party concentration, whereas this decision must address cross-team milestone dependency. The relevant first comparison is: Map the identity end-to-end transaction and identify team-specific control dependencies.
A risk owner seeks evidence following review of this situation: An authentication fix depends on directory, application and help-desk teams but the treatment plan names only the application developer. Which evidence would best demonstrate that the intended risk response is functioning?
Milestones demonstrate directory policy, app integration and recovery workflow all operate together. This evidence addresses the stated risk rather than showing only that a control was configured. Complex risk treatment often depends on coordinated controls across multiple owners.
Dashboards distinguish policy enforcement coverage from workflow productivity and risk trends. That observation may help validate kpi versus kci confusion, but it does not establish the acceptance condition for cross-team milestone dependency. Here, the decisive evidence is: Milestones demonstrate directory policy, app integration and recovery workflow all operate together.
Recovery tests demonstrate dispatch continuity and insurance terms specify covered financial claims. That observation may help validate risk transfer limitations, but it does not establish the acceptance condition for cross-team milestone dependency. Here, the decisive evidence is: Milestones demonstrate directory policy, app integration and recovery workflow all operate together.
Sampled production changes demonstrate timely approvals or tracked, justified exceptions. That observation may help validate design versus operating effectiveness, but it does not establish the acceptance condition for cross-team milestone dependency. Here, the decisive evidence is: Milestones demonstrate directory policy, app integration and recovery workflow all operate together.
or Guarantee your success by buying the full version which covers the full latest pool of questions. (1105 Questions, Last Updated on Nov 10, 2026)
Please check your mailbox for a message from support@examlabs.com and follow the directions.